We looked for p16/p19 deletion and p16 promoter methylation, as well as loss of 9p21 heterozygosity in pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with SCC components. Homozygous deletion of p16/p19 was detected in 11 of 21 (52%) cases of pure SCCs and in three of ten (30%) cases of TCC with SCC. Three cases of TCC with SCC had p16/p19 deletion, hypermethylation of the p16 promoter, or LOH on 9p21 only in the SCC components, suggesting that these molecular alterations occurred preferentially in SCC. Interestingly, homozygous deletion of p16/p19 was observed in squamous metaplasia from bladder cancer patients (®ve of 11, 45%), showing that this change occurred in preneoplastic cells. On the other hand, p16/p19 deletions were not found in squamous metaplasias from non cancerous patients. Hypermethylation of the p16 promoter was observed in two of 14 tumors (14%) and none of seven metaplasias examined. These data suggest that: (a) p16/p19 deletion is associated with early carcinogenesis of SCC of the bladder, and squamous metaplasia of the bladder cancer patient has already sustained genetic changes found in cancer, and (b) genetic mosaicism occurs in cases of TCC with SCC, with the SCC component showing more frequent 9p21 alterations than the TCC component.
Introduction
The p16 tumor suppressor gene is located on human chromosome 9p21, and the gene product inhibits cell cycle progression by binding cyclin D and cyclin dependent kinase (CDK) 4 and 6 thus inhibiting Rb phosphorylation (Serrano et al., 1993) . Another cell cycle regulatory gene, p19, is also located on chromosome 9p21, approximately 20 kb centomeric to exon 1 of p16 (Duro et al., 1995) . The p19 gene shares the same exon 2 as p16, but due to alternative reading frames, p16 and p19 have no amino acid sequence similarities (Quelle et al., 1995) . While p19 does not bind to CDKs, its overexpression leads to cell cycle arrest both in G1 and G2 phases (Quelle et al., 1995) . These two genes are frequently deleted in several kinds of tumors (Kamb et al., 1994; Nobori et al., 1994; Cairns et al., 1995) . De novo methylation of the 5'CpG island in the promoter of p16, which inhibits the expression of p16 but not p19 Gonzalgo et al., 1998) , is another mechanism of the gene silencing, and has been reported to occur frequently in a variety of cancers Fueyo et al., 1996; Gonzalez-Zulueta et al., 1995a; Wong et al., 1997; Ng et al., 1997; Herman et al., 1997) .
The frequency of homozygous deletion of p16/p19 in transitional cell carcinoma (TCC) of the bladder has been reported to range from 19 ± 71% (Kamb et al., 1994; Spruck et al., 1994a; Williamson et al., 1995; Orlow et al., 1995; Packenham et al., 1995) . Only two studies (Gonzalez-Zulueta et al., 1995b; Tamimi et al., 1996) have investigated the genetic status of p16/p19 in squamous cell carcinoma (SCC) of the bladder, which is another histological variant accounting for 5% of all bladder cancers in the United States (Young and Eble, 1991) but more than 75% in Egypt (Messing and Catalona, 1997) . A previous report by our laboratory showed a high frequency of 9p alterations and p16/p19 homozygous deletions both in schistosomal related and unrelated SCC of the bladder (Gonzalez-Zulueta et al., 1995b) . These and previously reported data on TCC which analysed p53 mutations and 9p deletions (Fujimoto et al., 1992; Miyao et al., 1993; Linnenbach et al., 1993; Ruppert et al., 1993; Keen and Knowles, 1994; Spruck et al., 1994b; Gonzalez-Zulueta et al., 1995b; Rosin et al., 1995; Simoneau et al., 1996) indicated that these two dierent histological types of bladder cancer dier in their genetic alterations. In contrast, Tamimi et al. (1996) reported that p16 alterations were more frequent in bladder tumors with schistosomiasis than those without schistosomiasis regardless of histological dierences. It is therefore still not clear as to whether alterations of p16/p19 depend on the histological type or etiology of the disease.
Squamous metaplasia of the bladder is a condition in which normal transitional epithelium is replaced by metaplastic squamous epithelium, and is often observed in patients with indwelling catheters or those with chronic or recurrent infections (Kaufman et al., 1977; El-Masri and Fellows, 1981; Navon et al., 1997) . This mucosal change is frequently observed in patients with spinal cord injuries, who have a 16 ± 28 times increased risk of squamous cell carcinoma of the bladder (Kaufman et al., 1977; El-Masri and Fellows, 1981) . Thus, it is thought that squamous metaplasia predisposes to development of bladder cancer, however genetic changes in the preneoplastic epithelium have not yet been reported.
In this study, we analysed 21 cases of pure SCC of the bladder unrelated to schistosomiasis. In addition, ten bladder cancer cases having both TCC and SCC components were analysed to reveal genetic dierences between TCC and SCC. Furthermore, in order to determine the roles of these genes during carcinogenesis, squamous metaplasias from both bladder cancer and non-cancer patients were also analysed for deletions of p16/p19 exon 2 and 9p21, and methylation of the p16 promoter region.
Results
A total of 31 bladder cancer cases (21 cases of pure SCC and ten cases of TCC with accompanying SCC) were screened for homozygous deletion of p16/p19, LOH of 9p21 region and methylation of p16 promoter. Examples of deletion analysis are shown in Figure 1 . Two bladder cancer cell lines were used as controls, RT4 for p16/p19 deletion and T24 for its retention. Using duplex PCR, RT4 demonstrated only a GAPDH signal, while T24 had both p16/p19 and GAPDH signals with the same intensities. Normal tissue from case 21 demonstrated both p16/p19 and GAPDH signals at every PCR cycle, whereas squamous metaplasia and SCC in situ did not. The invasive SCC showed faint p16/p19 signals at 26, 28 and 30 cycles, which were presumably derived from normal stromal cell contamination (Figure 1b ). D9S171 and D9S942 were informative in case 21, and the signals from the lower bands were signi®cantly decreased in squamous metaplasia, SCC in situ and invasive SCC (Figure 1c) . Thus, squamous metaplasia, SCC in situ and invasive SCC of case 21 demonstrated p16/p19 deletion and LOH of 9p21.
An example of methylation analysis of the p16 promoter region by the Ms-SNuPE method is illustrated in Figure 2 . Case 22 contained three dierent histological variants (Figure 2a ). Using three dierent Ms-SNuPE primers for the p16 promoter region (Figure 2b ), methylation was observed only in the SCC component (Figure 2c) .
Results of all the cases analysed are summarized in Figure 3 . Homozygous deletion of p16/p19 was observed in 14 cases of bladder cancer (45%), including 11 of 21 (52%) cases of pure SCC (cases 2, 6, 7, 9, 11 ± 13, 15, 16, 19, and 21) and three of ten (30%) cases of TCC with SCC (cases 23, 24 and 30). Two of 14 tumor samples (14%) showed hypermethylation of the p16 promoter region by Ms-SNuPE analysis (cases 8 and 22). LOHs of 9p21 were also detected in eleven of 21 (52%) cases of pure SCC (cases 2, 3, 6, 7, 9, 13, 15, 16, 18, 19, and 21) and four of ten (40%) cases of mixed histology (cases 23 ± 26). Tumors from cases 15, 16 and 24 (SCC only) showed deletion of p16/p19 and LOH of D9S1748, but retained heterozygosity for D9S942 which is located just 5 kb upstream from exon 1 of p16. The retention could result from ampli®cation of a small amount of normal DNA contamination from tumor stroma, and it has been suggested that this is indicative of a homozygous deletion in the tumor Reed et al., 1996) . Deletions of p16/p19 and/or LOH on 9p21 were frequently observed both in cases of pure SCC (13/21, 62%) and cases of TCC with SCC (5/10, 50%).
Ten cases of TCC with squamous dierentiation were studied by analysing genetic dierences among the dierent histological types (Figure 3b ). Homozygous deletion or promoter methylation were observed in two of ten (20%) of the TCC components (cases 23 and 30), four of ten (40%) of the SCC components (cases 22 ± 24 and 30), and one of two (50%) of the AC components (case 23). LOH on 9p21 were also detected in three of nine (33%) of the TCC components (cases 23 ± 25), four of nine (44%) of the SCC components (cases 22 ± 24 and 26), and one of two (50%) of the AC components (case 23). Dierent genetic alterations were observed among each histological type in cases 22, 24, 26. In case 24, the SCC showed homozygous deletion of p16 /p19 and LOH of D9S1748 and D9S171, although the TCC component has only LOH of D9S171. Likewise, in case 26 only the SCC component showed LOH of D9S171. In case 22, only the SCC component was hypermethylated although the other components, TCC and AC were not ( Figure 2 ). The SCC components demonstrated more LOH of 9p21 and p16/p19 deletions than TCC components. To determine the status of p16/p19 and LOH of 9p21 in premalignant epithelium, we analysed squamous metaplasia in 11 samples obtained from bladder cancer patients (cases 15 ± 21, 28 ± 31). Five out of 11 (45%) squamous metaplasia samples demonstrated p16/p19 deletion and LOH of 9p21 with atypical squamous metaplasia showing more frequent deletion than typical squamous metaplasia. In contrast, no p16/ p19 deletion or LOH of 9p21 were observed in eight squamous metaplasias derived from patients without cancer. Promoter methylation of p16 was not observed in any squamous metaplasia examined.
The frequencies of p16/p19 deletion, methylation of p16 promoter and LOH of 9p21 in each of the histological variants of bladder cancer patients, containing TCC, SCC and coexisting squamous metaplasia are summarized in Table 1 .
Discussion
The frequency of p16/p19 homozygous deletion has been reported to be 55 ± 67% in schistosomal related squamous cell carcinoma of the bladder (GonzalezZulueta et al., 1995b; Tamimi et al., 1996) . In these reports, schistosomal unrelated SCCs were also analysed, but the numbers were too few to reach a conclusion regarding the frequency of this genetic change in these tumors. We studied a larger series of SCC unrelated to schistosomiasis for deletion of p16/ p19, LOH of 9p21, and methylation of p16 promoter region. Sequencing of p16 was not performed for mutation analysis, because the amount of DNA from our microdissected samples was limited and point mutations of p16 are relatively rare in TCC (Kamb et al., 1994; Spruck et al., 1994a; Packenham et al., 1995) and SCC (Gonzalez-Zulueta et al., 1995b) of the bladder. In schistosomal unrelated pure SCC of the bladder, we demonstrated a high frequency of LOH of 9p21 and/or deletion of p16/p19 (67%).
TCC with focal squamous or glandular differentiation is a common histological variant, accounting for approximately 10% of bladder cancers (Young and Eble, 1991) . We analysed ten individual cases having both TCC and SCC components, and found that the SCC components contained more genetic aberrations than TCC in three cases which showed genetic mosaicism among dierent histological types. These results suggest that the SCC component is more genetically unstable than the TCC component in the cases with mixed histology. The genetic alteration of 9p21 containing p16/p19 may therefore have a positive role in the formation of SCC from TCC.
Methylation of the 5'CpG island of p16 is another mechanism for inactivation of this gene, and several tumors have been reported to show this alteration Gonzalez-Zulueta et al., 1995a; Fueyo et al., 1996; Wong et al., 1997; Ng et al., 1997; Herman et al., 1997) . In this report, methylation of p16 promoter was analysed in 15 tumor specimens from ten bladder cancer patients as well as seven squamous metaplasia specimens from two bladder cancer patients and ®ve cancer free patients. In these samples, only two bladder cancer cases showed p16 promoter hypermethylation. This result is lower than our previous observations (14% vs 67%) of p16 exon 1 methylation in bladder TCCs (Gonzalez-Zulueta et al., 1995a) which was measured by the PCR based methylation analysis (Singer-Sam et al., 1990) . We have, however, recently shown that methylation of the coding region in exon 1 does not inhibit the initiation of p16 transcription (Gonzalgo et al., 1998) . On the other hand, methylation of CpG island in the p16 promoter region prevents formation of the p16 transcript, but does not stop the formation of a transcript initiated 20 kb upstream at the p19 promoter (Gonzalgo et al., 1998) . The current results using quantitative Ms-SNuPE method to measure promoter methylation are more biologically relevant, and inactivation of the p16 promoter by methylation is less common in bladder cancer than previously thought.
Pathological and epidemiological studies (Kaufman et al., 1977; El-Masri and Fellows, 1981; Sakamoto et al., 1992; Navon et al., 1997) have indicated that squamous metaplasia is a premalignant lesion of SCC of the bladder, however its genetic alterations have not been previously analysed. In this study, squamous metaplasias from bladder cancer patients showed frequent (45%) homozygous deletions of p16/p19 and LOH of 9p21. Interestingly, atypical squamous metaplasia demonstrated more frequent homozygous deletion of p16/p19 and LOH on 9p21 than typical metaplasia. However, no genetic alterations were observed in typical squamous metaplasia from non cancerous patients. These results demonstrate that These results indicate that p16 promoter region is unmethylated in TCC and AC components, but hypermethylated in SCC atypical squamous metaplasia has already sustained genetic changes found in cancers, and suggest that p16/ p19 inactivation is an early genetic event in the pathogenesis of squamous cell carcinoma of the bladder. This is the ®rst report of homozygous deletions of p16/p19 in squamous metaplasia of the bladder, which is in agreement with the results by Ghaleb et al. (1996) . They reported that the squamous metaplasia from patients with long-standing severe schistosomal cystitis demonstrated monosomy 9 bȳ uorescence in situ hybridization. Our results suggest another possible pathway during squamous carcinogenesis. Some of the SCC components had alterations not present in the TCC components (cases 22, 24 and 26) which suggests that the SCC was derived from the TCC component rather than squamous metaplasia. This evolution for some mixed tumors has been suggested from previous pathological mapping studies of the bladder (Sakamoto et al., 1992) . However, it is still dicult to explain the carcinogenic pathway of the case which contains squamous metaplasia and TCC with squamous dierentiation.
In summary, we have demonstrated that alterations in p16/p19 occur at high frequency in SCC, and that the SCC components in mixed tumors show these genetic changes more frequently than the TCC components. We have also observed a high frequency of homozygous deletion of p16/p19 in squamous metaplasia of bladder cancer patients, but the deletion was not observed in squamous metaplasia from noncancerous patients.
Materials and methods

Samples and DNA isolation
Twenty-one cases of pure SCC and ten cases of TCC with SCC of the bladder were analysed. Two specimens contained three histological components, TCC, SCC and adenocarcinoma (AC) (cases 22 and 23), and eight cases showed TCC with squamous dierentiation (cases 24 ± 31). Case 21 had both invasive SCC and SCC in situ components, which were individually analysed. Eleven coexisting squamous metaplasias of cancer patients were also analysed, and they were categorized as typical squamous metaplasias (cases 17 ± 20 and 31) and atypical squamous metaplasias (cases 15, 16, 21 and 28 ± 30) . The replacement of transitional cells by well-dierentiated, mature strati®ed squamous epithelium with or without keratinization was de®ned as`typical squamous metaplasia', whereas a thickened basal layer with the presence of cells having increased nuclear to cytoplasmic ratios and hyperchromatic nuclei was de®ned as`atypical squamous metaplasia'. Each dierent component was independently microdissected. Eight squamous metaplasias were also , homozygous deletion; , LOH; , retention of heterozygosity; NI, not informative; no mark, not examined. The`?' marks of cases 15, 16 and 24 indicate possible homozygous deletions which could not be con®rmed. The average percentages of methylation of three CpG sites in p16 promoter region measured by Ms-SNuPE analysis are indicated as numbers below the deletion analysis. At. meta, atypical metaplasia; Meta, typical metaplasia available from cystectomy specimens removed from patients with poorly functioning neurogenic bladders (cases 32 ± 39). The sections were examined by one pathologist (PWN) to con®rm histological classi®cation. The tissue was isolated from formalin-®xed paran embedded tissue specimens by microdissection, and resuspended in 10 mM Tris-HCl buer (pH 8.3) containing 5 mM EDTA and treated at 558C overnight with proteinase-K at a ®nal concentration of 1 mg/ml.
Analysis of homozygous deletion of p16/p19 gene Heminested duplex PCR was used to amplify exon 2 of p16/p19. For the ®rst round PCR the primers were: 5'-GAC CCG TGC ACG ACG CT-3' (within exon 2) and 5'-TGA GCT TTG GAA GCT CTC AG-3' (in intron 2). For the second round of PCR, the primers were 5'-GAC CCG TGC ACG ACG CT-3' and 5'-GGT-ACC GTG CGA CAT CGC-3' (both within exon 2). GAPDH was selected as an internal control. Primer sets used for amplifying DNA were 5'AAG GAG ATG CTG -CAT TCG CCC TCT TA-3' and 5'-TCA TTG ATG-GCA ACA ATA TCC ACT-3' for the ®rst round PCR, and 5'-AAG GAG ATG CTG CAT TCG CCC TCT-TA-3' and 5'-CCA ATA CGA CCA AAT CTA AGA -GAC-3' for the second round PCR. Duplex PCR reactions were performed in a 15 ml volume and included primer sets for both GAPDH and p16/p19 at ®nal concentration of 0.1 and 1 mM, respectively. The reaction mixture also contained 5% dimethyl sulfoxide, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 400 mM of each deoxynucleoside triphosphate, and 1.5 U of Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN). Conditions for the ®rst round PCR were as follows: 948C for 2 min, 17 cycles of 948C for 1 min, 558C for 40 s, 728C for 1 min, followed by incubation at 728C for 2 min. One microliter of each reaction product was used as template for the second round of PCR ampli®cation. Conditions for the second round PCR were as follows: 948C for 2 min, a series of 24, 26, 28 and 30 cycles of 948C for 1 min, 588C for 40 s, 728C for 1 min, followed by incubation at 728C for 2 min. Buer components of the second PCR were the same as the ®rst round ampli®cation except that 0.2 mCi [aP 33 ]deoxyadenine triphosphate (dATP) (10 mCi/ml; ICN Biochemicals Inc. Costa Mesa, CA) was added to each reaction mixture. PCR products were resolved on non-denaturing 7% polyacrylamide gels.
Normal cell contamination in tumor specimens is one potential problem for quantitation by PCR, because a small amount of DNA from normal cells can produce a disproportionately strong signal. To control for this potential artifact, we tested four mixtures of RT4 and T24 cell line DNAs, since p16/p19 is homozygously deleted in RT4, but retained in T24 (Spruck et al., 1994a) . Our heminested duplex PCR is able to detect homozygous deletions when DNA from the deleted tissue contains less than 10% DNA from the cells which had retained the p16/p19 loci (data not shown). All tumor tissues were carefully microdissected to obtain approximately less than 5% normal cell contamination. Another diculty in detecting homozygous deletions is quanti®cation of signals during the exponential phase of PCR. If the PCR reaction is cycled beyond the plateau phase, contaminating normal cell DNA can contribute to the p16/p19 band, thus leading to an under-estimation of the frequency of p16/p19 homozygous deletion. A series of four dierent cycles for second round PCR were therefore performed for each sample, and each signal was quanti®ed by phosphoimager analysis. Homozygous deletion was scored based on the signi®cantly decreased ratio of signal intensity of p16/ GAPDH of the tumor DNAs. IN, USA) . Annealing temperature varied between 55 ± 608C, and cycle number varied from 30 ± 35, depending on primer sets. PCR products were resolved on 7% polyacrylamide /7M urea gels, and allelic loss was scored in the informative cases when the intensity of the signal for tumor allele was signi®cantly less than that of the matched normal allele.
Methylation analysis of p16 promoter region
The samples which did not show p16/p19 deletion were analysed quantitatively for methylation of the p16 promoter region using methylation-sensitive single nucleotide primer extension (Ms-SNuPE) (Gonzalgo and Jones, 1997) . Fifteen samples from ten bladder cancer patients (cases 3, 4, 8, 10, 14, 18, 22, 24, 26, and 29) and ®ve squamous metaplasias from neurogenic bladder patients (cases 32, 34, 35, 38 and 39) were available for analysis.
DNA was treated with sodium bisul®te as described previously (Clark et al., 1994) . Treatment of genomic DNA with sodium bisul®te causes unmethylated cytosine to be converted to uracil which is subsequently replicated as thymine during PCR, while methylcytosine is resistant to deamination and is replicated as cytosine. The PCR was performed for 38 cycles at 948C 30 s, 688C 30 s and 728C 30 s in 15 ml containing approximately 5 ng bisul®te treated DNA, 100 mM dNTP, 2.0 mM MgCl 2 , and 1 unit of Expand enzyme (Boehringer Mannheim, Indianapolis, IN, USA) with 0.5 mM primers (5'-GTA GGT GGG GAG GAG TTT AGT T-3' and 5'-TCT AAT AAC CAA CCA ACC CCT CC-3'). After purifying the PCR product, MsSNuPE reactions were performed as described previously (Gonzalgo and Jones, 1997) . Three dierent primers were used to determine methylation on the p16 promoter. (Primer 1; 5'-TTT TTT TGT TTG GAA AGA TAT-3', Primer 2; 5'-TTT TAG GGG TGT TAT ATT-3', Primer 3; 5'-TTT GAG GGA TAG GGT-3'). Samples were loaded onto 15% denaturing polyacrylamide gels. Radioactivities of bands were measured by phosphoimager analysis, and the average percentage of methylation of three sites was calculated.
